NanoCell Therapeutics, Inc. is a company developing a new biological entity-based targeted gene therapy platform, with the vision to make cell engineered therapies affordable, scalable, and accessible for the general patient population. Our cell-directed polymeric nanoparticle technology is able to deliver DNA plasmids and RNA to specific cells of interest, such as T cells, upon i.v. administration. Our new class of medicines has the potential to transform CAR-T and TCR therapies and beyond. Our cell-directed bio-responsive nanoparticles can also be directed to monocytes, NK cells, B cells, monocytes, hepatocytes, endothelial cells, and many other cell types, which broadens the spectrum of applicable clinical indications beyond oncology to include autoimmune/inflammatory, infectious, cardiovascular, protein/enzyme deficiency, and other diseases.